Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Non-Current Assets (2022 - 2025)

Praxis Precision Medicines has reported Non-Current Assets over the past 4 years, most recently at $327.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $327.0 million for Q4 2025, up 315.3% from a year ago — trailing twelve months through Dec 2025 was $741.0 million (up 187.31% YoY), and the annual figure for FY2025 was $327.0 million, up 315.3%.
  • Non-Current Assets for Q4 2025 was $327.0 million at Praxis Precision Medicines, up from $122.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PRAX hit a ceiling of $327.0 million in Q4 2025 and a floor of $3.1 million in Q4 2023.
  • Median Non-Current Assets over the past 4 years was $21.8 million (2022), compared with a mean of $64.5 million.
  • Biggest five-year swings in Non-Current Assets: decreased 28.45% in 2023 and later skyrocketed 2466.43% in 2024.
  • Praxis Precision Medicines' Non-Current Assets stood at $4.3 million in 2022, then dropped by 28.45% to $3.1 million in 2023, then skyrocketed by 2466.43% to $78.7 million in 2024, then surged by 315.3% to $327.0 million in 2025.
  • The last three reported values for Non-Current Assets were $327.0 million (Q4 2025), $122.5 million (Q3 2025), and $146.3 million (Q2 2025) per Business Quant data.